The rate of breast cancer deaths in the U.S. has dramatically declined since 1950. As of 2023, the death rate from breast cancer was **** per 100,000 population. However, cancer is a serious public health issue in the United States and is the second leading cause of death among women. Breast cancer incidence Breast cancer symptoms include lumps or thickening of the breast tissue and may include changes to the skin. Breast cancer is driven by many factors, but age is a known risk factor. Among all age groups, the highest number of invasive breast cancer cases were among those aged 60 to 69. The incidence rate of new breast cancer cases is higher in some ethnicities than others. White, non-Hispanic women have the highest incidence rate of breast cancer, followed by non-Hispanic Black women. Breast cancer treatment Breast cancer treatments usually involve several methods, including surgery, chemotherapy and biological therapy. Types of cancer diagnosed at earlier stages often require fewer treatments. A majority of early stage breast cancer cases in the U.S. receive breast conserving surgery and radiation therapy.

Editor’s Choice

• Global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022, growing at a CAGR of 9.8% during the forecast period from 2022 to 2032.
• Breast cancer is the most common cancer among women worldwide. In 2020, there were about 2.3 million new cases of breast cancer diagnosed globally.
• Breast cancer is the leading cause of cancer-related deaths in women. In 2020, it was responsible for approximately 685,000 deaths worldwide.
• The survival rate of breast cancer has improved over the years. In the United States, the overall five-year survival rate of breast cancer is around 90%.
• The American Cancer Society recommends annual mammograms starting at age 40 for women at average risk.
• Although rare, breast cancer also occurs in men. Less than 1% of breast cancer cases are diagnosed in males.

(Source: WHO, American Cancer Society)

In 2023, there were **** deaths from breast cancer per 100,000 population in the state of South Dakota, the lowest of any state that year. This statistic shows the death rate from breast cancer in the U.S. in 2023, by state.

Deaths from breast cancer in females registered in the calendar year, directly standardized by age group, given as a rate per 100,000 registered female patients.

In 2022, the mortality rate of breast cancer in women in Europe was **** per 100,000 women. Cyprus had the highest mortality rate at **** per 100,000, followed by Slovakia with **** per 100,000 women. Conversely, Spain had the lowest mortality rate at **** per 100,000. This statistic depicts the mortality rate of breast cancer in Europe in 2022 in women population, by country.

In 2022, 175 females per 100,000 population were registered in England as newly diagnosed with breast cancer. This was an overall increase in comparison to the last few years' rate of registration. This statistic shows the rate of newly diagnosed female cases of breast cancer per 100,000 population in England from 1995 to 2022.

Mortality from breast cancer (ICD-10 C50 equivalent to ICD-9 174). To reduce deaths from breast cancer. Legacy unique identifier: P00159

Dataset Description This dataset contains information on cancer deaths by country, type, and year. It includes data on 18 different types of cancer, including liver cancer, kidney cancer, larynx cancer, breast cancer, thyroid cancer, stomach cancer, bladder cancer, uterine cancer, ovarian cancer, cervical cancer, prostate cancer, pancreatic cancer, esophageal cancer, testicular cancer, nasopharynx cancer, other pharynx cancer, colon and rectum cancer, non-melanoma skin cancer, lip and oral cavity cancer, brain and nervous system cancer, tracheal, bronchus, and lung cancer, gallbladder and biliary tract cancer, malignant skin melanoma, leukemia, Hodgkin lymphoma, multiple myeloma, and other cancers.

Data Fields The dataset includes the following data fields:

• Country: The country where the cancer death occurred.
• Code: The country code for the country where the cancer death occurred.
• Year: The year in which the cancer death occurred.
• Liver cancer: The number of cancer deaths from liver cancer in the country in the year.
• Kidney cancer: The number of cancer deaths from kidney cancer in the country in the year.
• Larynx cancer: The number of cancer deaths from larynx cancer in the country in the year.
• Breast cancer: The number of cancer deaths from breast cancer in the country in the year.
• Thyroid cancer: The number of cancer deaths from thyroid cancer in the country in the year.
• Stomach cancer: The number of cancer deaths from stomach cancer in the country in the year.
• Bladder cancer: The number of cancer deaths from bladder cancer in the country in the year.
• Uterine cancer: The number of cancer deaths from uterine cancer in the country in the year.
• Ovarian cancer: The number of cancer deaths from ovarian cancer in the country in the year.
• Cervical cancer: The number of cancer deaths from cervical cancer in the country in the year.
• Prostate cancer: The number of cancer deaths from prostate cancer in the country in the year.
• Pancreatic cancer: The number of cancer deaths from pancreatic cancer in the country in the year.
• Esophageal cancer: The number of cancer deaths from esophageal cancer in the country in the year.
• Testicular cancer: The number of cancer deaths from testicular cancer in the country in the year.
• Nasopharynx cancer: The number of cancer deaths from nasopharynx cancer in the country in the year.
• Other pharynx cancer: The number of cancer deaths from other pharynx cancer in the country in the year.
• Colon and rectum cancer: The number of cancer deaths from colon and rectum cancer in the country in the year.
• Non-melanoma skin cancer: The number of cancer deaths from non-melanoma skin cancer in the country in the year.
• Lip and oral cavity cancer: The number of cancer deaths from lip and oral cavity cancer in the country in the year.
• Brain and nervous system cancer: The number of cancer deaths from brain and nervous system cancer in the country in the year.
• Tracheal, bronchus, and lung cancer: The number of cancer deaths from tracheal, bronchus, and lung cancer in the country in the year.
• Gallbladder and biliary tract cancer: The number of cancer deaths from gallbladder and biliary tract cancer in the country in the year.
• Malignant skin melanoma: The number of cancer deaths from malignant skin melanoma in the country in the year.
• Leukemia: The number of cancer deaths from leukemia in the country in the year.
• Hodgkin lymphoma: The number of cancer deaths from Hodgkin lymphoma in the country in the year.
• Multiple myeloma: The number of cancer deaths from multiple myeloma in the country in the year.
• Other cancers: The number of cancer deaths from other cancers in the country in the year.

Data Source The data in this dataset was collected from the World Health Organization (WHO). The WHO collects data on cancer deaths from countries around the world.

Usage This dataset can be used to study cancer deaths by country, type, and year. It can also be used to compare cancer death rates between different countries or over time.

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16169071%2F98f6c6f321aad496b703685519b6df6a%2Fcancer-cells-th.jpg?generation=1694610742970317&alt=media" alt="">

BackgroundThis nationwide study examined breast cancer (BC) incidence and mortality rates in Hungary between 2011–2019, and the impact of the Covid-19 pandemic on the incidence and mortality rates in 2020 using the databases of the National Health Insurance Fund (NHIF) and Central Statistical Office (CSO) of Hungary.MethodsOur nationwide, retrospective study included patients who were newly diagnosed with breast cancer (International Codes of Diseases ICD)-10 C50) between Jan 1, 2011 and Dec 31, 2020. Age-standardized incidence and mortality rates (ASRs) were calculated using European Standard Populations (ESP).Results7,729 to 8,233 new breast cancer cases were recorded in the NHIF database annually, and 3,550 to 4,909 all-cause deaths occurred within BC population per year during 2011-2019 period, while 2,096 to 2,223 breast cancer cause-specific death was recorded (CSO). Age-standardized incidence rates varied between 116.73 and 106.16/100,000 PYs, showing a mean annual change of -0.7% (95% CI: -1.21%–0.16%) and a total change of -5.41% (95% CI: -9.24 to -1.32). Age-standardized mortality rates varied between 26.65–24.97/100,000 PYs (mean annual change: -0.58%; 95% CI: -1.31–0.27%; p=0.101; total change: -5.98%; 95% CI: -13.36–2.66). Age-specific incidence rates significantly decreased between 2011 and 2019 in women aged 50–59, 60–69, 80–89, and ≥90 years (-8.22%, -14.28%, -9.14%, and -36.22%, respectively), while it increased in young females by 30.02% (95%CI 17,01%- 51,97%) during the same period. From 2019 to 2020 (in first COVID-19 pandemic year), breast cancer incidence nominally decreased by 12% (incidence rate ratio [RR]: 0.88; 95% CI: 0.69–1.13; 2020 vs. 2019), all-cause mortality nominally increased by 6% (RR: 1.06; 95% CI: 0.79–1.43) among breast cancer patients, and cause-specific mortality did not change (RR: 1.00; 95%CI: 0.86–1.15).ConclusionThe incidence of breast cancer significantly decreased in older age groups (≥50 years), oppositely increased among young females between 2011 and 2019, while cause-specific mortality in breast cancer patients showed a non-significant decrease. In 2020, the Covid-19 pandemic resulted in a nominal, but not statistically significant, 12% decrease in breast cancer incidence, with no significant increase in cause-specific breast cancer mortality observed during 2020.

This is a very simple dataset that contains the total female breast cancer deaths in Mexico by year of registration.

This dataset was compiled using the open data from INEGI, from the year 1998 to 2022.

https://www.inegi.org.mx/programas/mortalidad/#microdatos

The population estimates are from CONAPO.

https://datos.gob.mx/busca/dataset/proyecciones-de-la-poblacion-de-mexico-y-de-las-entidades-federativas-2020-2070/resource/79109217-1612-4955-9b66-06b21e27238c

Number and rate of new cancer cases diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

BACKGROUND Comprehensive analyses of statistical data on breast cancer incidence, mortality, and associated risk factors are of great value for decision-making related to reducing the disease burden of breast cancer. METHODS: Based on data from the Annual Report of China Tumour Registry and the Global Burden of Disease (GBD), we conducted summary and trend analyses of incidence and mortality rates of breast cancer in Chinese women from 2014 to 2018 for urban and rural areas in the whole, eastern, central, and western parts of the country, and projected the incidence and mortality rates of breast cancer for 2019 in comparison with the GBD 2019 estimates. And the comparative risk assessment framework estimated risk factors contributing to breast cancer deaths and disability-adjusted life years (DALYs) from GBD. RESULTS: The Annual Report of the Chinese Tumour Registry showed that showed that the mortality rate of breast cancer declined and the incidence rate remained largely unchanged from 2014 to 2018. There was a significant increasing trend in incidence rates among urban and rural women in eastern China and rural women in central China, whereas there was a significant decreasing trend in mortality rates among rural women in China. The two data sources have some differences in their predictions of breast cancer in China in 2019. The GBD data estimated the age-standard DALYs rates of high body-mass index, high fasting plasma glucose and diet high in red meat, which are the top three risk factors attributable to breast cancer in Chinese women, to be 29.99/100,000, 13.66/100,000 and 13.44/100,000, respectively. Conclusion: The trend of breast cancer incidence and mortality rates shown in the Annual Report of China Tumour Registry indicates that China has achieved remarkable results in reducing the burden of breast cancer, but there is still a need to further improve breast cancer screening and early diagnosis and treatment, and to improve the system of primary prevention. The GBD database provides risk factors for breast cancer in the world, Asia, and China, and lays the foundation for research on effective measures to reduce the burden of breast cancer.

Mortality from breast cancer (ICD-10 C50 equivalent to ICD-9 174). To reduce deaths from breast cancer. The next release date for this indicator is to be confirmed. Legacy unique identifier: P00147

Death rate has been age-adjusted to the 2000 U.S. standard population. Single-year data are only available for Los Angeles County overall, Service Planning Areas, Supervisorial Districts, City of Los Angeles overall, and City of Los Angeles Council Districts.Obesity can increase an individual’s lifetime risk of breast cancer. Promoting healthy food retail and physical activity and improving access to preventive care services are important measures that cities and communities can take to prevent breast cancer.For more information about the Community Health Profiles Data Initiative, please see the initiative homepage.

This data package contains information on cancer its type, its occurrence by age, type and site. It also provides detailed data on adult and childhood cancer survival rates and deaths caused by breast cancer in females.

Deaths from breast cancer - Directly age-Standardised Rates (DSR) per 100,000 population Source: Office for National Statistics (ONS) Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Primary Care Trust (PCT), Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2005-07, 2007 Type of data: Administrative data

This statistic shows the number of breast cancer deaths in the United States from 1999 to 2021, by gender. The highest number of breast cancer deaths in the given period was 42,465, reported in 2018. The lowest number was reported in 2008, with 40,589 deaths.

The population of Middle Tennessee was assessed using publically available data collected in 2009 describing demographic and breast cancer-related characteristics of the population.*The value for each breast cancer risk factor was determined for each Middle Tennessee County, and counties were then ranked in numerical order from lowest to highest. The numerically ranked counties were then subdivided into quartiles, such that the three counties with the lowest risk factor values were placed in Quartile 1, and those with the highest were placed in Quartile 4. The range of risk factor values encompassed by each quartile are shown.1The percentage of the total female population in the county that is over the age of 50 years (a surrogate for menopause).2The breast cancer incidence per 100,000 women. 3Breast cancer mortality per 100,000 women.4The percentage of all breast cancers that were diagnosed at Stage IV.5The percentage of all breast cancers that were diagnosed without a prior mammographic screening.6The percentage of the female population lacking any form of health insurance.7The median household income.8The percentage of the population possessing higher than a high school level education.9The percentage of the population that is not Caucasian.

Rate: Number of new cases of breast cancer (per 100,000) diagnosed at the regional or distant stage among females.

Definition: Age-adjusted incidence rate of invasive breast cancer per 100,000 female population.

Data Sources:

(1) NJ State Cancer Registry, Dec 31, 2015 Analytic File, using NCI SEER*Stat ver 8.2.1 (www.seer.cancer.gov/seerstat)

(2) NJ population estimates as calculated by the NCI's SEER Program, released January 2015, http://www.seer.cancer.gov/popdata/download.html.

BackgroundCardiovascular disease (CVD) is the leading cause of morbidity and mortality among older postmenopausal women. The impact of postmenopausal breast cancer on CVD for older women is uncertain. We hypothesized that older postmenopausal women with breast cancer would be at a higher risk of CVD than similar aged women without breast cancer and that CVD would be a major contributor to the subsequent morbidity and mortality.MethodsIn a prospective Women’s Health Initiative study, incident CVD events and total and cause-specific death rates were compared between postmenopausal women with (n = 4,340) and without (n = 97,576) incident invasive breast cancer over 10 years post-diagnosis, stratified by 3 age groups (50–59, 60–69, and 70–79).ResultsPostmenopausal women, regardless of breast cancer diagnosis, had similar and high levels of CVD risk factors (e.g., smoking and hypertension) at baseline prior to breast cancer, which were strong predictors of CVD and total mortality over time. CVD affected mostly women age 70–79 with localized breast cancer (79% of breast cancer cases in 70–79 age group): only 17% died from breast cancer and CVD was the leading cause of death (22%) over the average 10 years follow up. Compared to age-matched women without breast cancer, women age 70–79 at diagnosis of localized breast cancer had a similar multivariate-adjusted hazard ratio (HR) of 1.01 (95% confidence interval [CI]: 0.76–1.33) for coronary heart disease, a lower risk of composite CVD (HR = 0.84, 95% CI: 0.70–1.00), and a higher risk of total mortality (HR = 1.20, 95% CI: 1.04–1.39).ConclusionCVD was a major contributor to mortality in women with localized breast cancer at age 70–79. Further studies are needed to evaluate both screening and treatment of localized breast cancer tailored to the specific health issues of older women.